- Meridian Bioscience (NASDAQ:VIVO +2.3%) FQ2 results: Revenues: $51.5M (+2.8%); COGS: $19M (+2.7%); Operating Expenses: $16.8M (+5.7%); Operating Income: $15.7M (+0.4%); Net Income: $10.1M (-1.9%); EPS: $0.24 (unch); Quick Assets: $42.7M (11.8%).
- 2015 Guidance: Net Revenues: $193M - 200M, EPS: $0.85 - 0.91.